Probiotic agents for ulcerative colitis: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 8, Issue 5, 2008, Pages 315-321

  Wu, Qiu Rong ^a   Zhou, Jun ^a   He, Ji Dong ^a   Wang, Yi Ping ^b   Yang, Xiu Rong ^a   Zhang, Lan ^a  

^a Ya'an People's Hospital   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Meta analysis; Probiotic agents; Randomized controlled trial; Systematic review; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; PLACEBO; PROBIOTIC AGENT;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; MORBIDITY; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 51449083342     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis, 2004, 10(3): 286-299.
2. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis, 2000, 6(2): 107-115.
3. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hapatol, 2003, 15(6): 697-698.
4. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis, 2004, 10(5): 646-651.
5. Heriasm V, Koninkx JF, Vos JG, et al. Probiotic effects of Lactobacillus caseion DSS - induced ulcerative colitis in mice. Int J Food Microbiol, 2005, 103(2): 143-155.
6. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther, 1999, 13(9): 1103-1108.
7. Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol, 2004, 10(10): 1521-1525.
8. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther, 2004, 20(9): 1133-1141.
9. Hideki I, Ikuko A, Yoshinori U, et al. Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis. Journal of the American College of Nutrition, 2002, 22(1): 56-63.
10. Antonio T, Giovanni B, Gian Marco G, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit, 2004, 10(11): 126-131.
11. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, 53(11): 1617-1623.
12. Kruis W, Schutz E, Fric P, et al. double-blind comparison of an oral Escherichia coli preparation and mesalazine in Maintaining remission of ulcerative colitis. Aliment Pharmacol Ther, 1997, 23(11): 853-858.
13. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1)initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut, 2005, 54(9): 242-249.
14. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet, 1999, 35(4): 635-639.
15. Zocco M A, ZileridavermeIL, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther, 2006, 23(11): 1567-1574.
16. Chinese source
17. Chinese source
18. Chinese source
19. Chinese source
20. Shanahan F. Probiotics and inflammatory bowel disease : from fads and fantasy to facts and future. Br J Nutr, 2002, 88(suppl 1): S5.
21. McCarthy J, Mahony LO, Callaghan LO, et al. Double blind, placebo controlled trail of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut, 2003, 52(6): 975.
22. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cell from the effects of Infection with enteroin-vasive Escherichia colis. Gut, 2003, 52(7): 988-997.
23. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology, 2001, 112(3): 580-591.